Dr. Silverman studies the fundamental aspects of early-life commensal microbes that influence immune system development and function. He discovered that the MHC-II E molecule prevents type 1 diabetes by shaping the intestinal microbiota early in life.
Dr. Hill seeks to understand how the immune system contributes to the two most common chronic diseases of childhood: allergy and obesity. He uses clinical and epidemiological information to guide basic and translational research on the genetic, epigenetic, and immunologic basis of these important conditions.
Dr. Romberg investigates the regulatory mechanisms enabling our immune systems to fight infections without injuring ourselves. He is particularly interested in the immune system of patients with primary immunodeficiency who are susceptible to both life-threatening infections and autoimmune diseases. Greater insights into these rare diseases may enable rationale development of targeted therapies for more common diseases with an immunologic basis.
Dr. Levy-Erez's research is focused on the discovery of immune urinary biomarkers among children developing acute kidney injury. She is studying both a unique population of immune-compromised children after hematopoietic stem cell transplantation (HSCT) as well as children who have an intact immune system who develop acute kidney injury after cardiac bypass surgery.
Dr. Sgourakis’ research focuses on understanding the intricate molecular mechanisms that determine the vast repertoire of peptide antigens displayed by the proteins of the Major Histocompatibility Complex for immune surveillance by T cells and Natural Killer cells.
Dr. Heuckeroth investigates mechanisms controlling bowel motility in order to find new ways to treat, diagnose, and prevent intestinal motility disorders. He works to define genetic, biochemical, and cellular processes that impact bowel function, with a special interest in the enteric nervous system and intestinal smooth muscle cells.
Dr. Behrens' research focuses on the pathogenesis and treatment of cytokine storm syndromes, including the hemophagocytic syndromes Hemophagocytic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS).
Dr. Marks investigates the molecular mechanisms underlying the formation of cell type-specific lysosome-related organelles; the assembly, delivery and function of their contents; and how these processes are impacted by genetic diseases.
The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.